Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- EU Panel Confirms Nod for Kissei-Originated Fibroid Drug
April 26, 2022
- Shionogi’s COVID-19 Pill Improves Respiratory and Feverish Symptoms
April 26, 2022
- Chugai’s Q1 Sales Double on Ronapreve Bonanza, Brisk Hemlibra Export
April 26, 2022
- Mitsubishi Tanabe’s Oral Edaravone Accepted for Swiss Review in ALS
April 26, 2022
- Janssen Files Label Expansion for Imbruvica in Japan
April 26, 2022
- Ono Seeks Japan Neoadjuvant Nod for Opdivo in NSCLC
April 26, 2022
- KM Biologics Files DTaP-IPV-Hib Vaccine in Japan
April 26, 2022
- Astellas to Write Off Massive Losses over AT132, DMD Gene Therapies
April 25, 2022
- Large-Scale Japan Trial for Shionogi Jab Confirms No Major Safety Concerns, Increase in Antibody Titers
April 25, 2022
- Investigator-Led Trial Begins for FunPep’s Antibody-Inducing Peptide
April 25, 2022
- Sumitomo to Build Cell Processing Center in US, Completion Set for FY2023
April 25, 2022
- Kowa Bags Japan Marketing Rights for Teikoku Seiyaku’s Donepezil Tape
April 22, 2022
- Hisamitsu Files Palmar Hyperhidrosis Drug in Japan, Eyes Approval in FY2023
April 22, 2022
- MSD Japan’s Sales Surge 7.5% in 2021, 1.5% Growth If Lagevrio Excluded: President
April 22, 2022
- Sumitomo Expects Further Growth for Latuda, Lonasen; Recognition by Physicians Holds Key: Sales Chief
April 22, 2022
- KM Biologics to Soon Begin Pediatric PII/III for COVID Jab, 1st Japan Trial to Include Kids below Age 5
April 21, 2022
- Novo Japan’s Sales Hit 100 Billion Yen Mark in 2021, but President Frets Future Investments
April 21, 2022
- KM Biologics to File COVID-19 Vaccine as Early as September, Chancing Emergency Approval
April 21, 2022
- GSK Japan Chief Has High Hopes for Shingrix, Blenrep, RSV Jab as Future Growth Drivers
April 21, 2022
- Lumakras, Bimzelx, Pivlaz Now Available in Japan
April 21, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…